Edwards Lifesciences 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or
15(d) of the
Date of report (Date of earliest event reported): October 25, 2005
EDWARDS LIFESCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-Commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
This information furnished under this Item 2.02, including Exhibit 99.1 shall not be deemed to be filed for purposes of the Securities Exchange Act of 1934, as amended (the Exchange Act) except that the information contained in the first two paragraphs of Exhibit 99.1 and pages 6 through 12, inclusive, shall be considered to be filed under the Exchange Act.
On October 25, 2005, Edwards Lifesciences Corporation, a Delaware corporation (Edwards), issued a press release setting forth Edwards financial results for the third quarter of 2005. A copy of the press release is attached as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
99.1 Press release, dated October 25, 2005, reporting Edwards financial results for the third quarter of 2005.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.